Related Experiment Video
Updated: Oct 26, 2025
Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
New horizons in early drugs development in solid cancers
Nuria Kotecki1, Nadège Kindt2, Mohammad Krayem2
1Oncology Medicine Department.
Purpose Of Review:
Drug development is the process of bringing new anticancer agents into clinical practice. From the basic research to clinical research each step is essential and intimately linked. The aim of this review is to describe emerging preclinical models and to provide an overview of selected drugs recently developed in oncology.
Recent Findings:
Preclinical models reproducing human immune-tumor interactions, 3D cell cultures and microfluidic platforms are of great interest for the development of immunotherapies and combination therapies and offer the opportunity to better understand the interplay between cancer and stromal cells.Following a better biological understanding of cancer and advances in precision oncology, new exciting drugs (e.g. antibodies-drugs conjugates [ADCs], immunotherapeutic strategies, molecular-targeted therapies) have entered the field of clinical research and even clinical practice.
Summary:
Recent improvements in preclinical models will allow an accurate selection of drug candidates for clinical research. Innovative drugs are currently being developed from early to later phases of development. An important remaining challenge in drug development is to set up a new model of patient-centered clinical research to facilitate quick access to innovation and target-oriented trials.
Insights
Emerging preclinical models enhance the selection of anticancer drugs. Advances in oncology are driving the development of novel immunotherapies and targeted therapies for improved cancer treatment.
Area of Science:
- Oncology
- Drug Development
- Preclinical Research
Background:
- Drug development progresses from basic research to clinical application, with each stage being critical.
- Understanding cancer biology and precision oncology fuels the development of novel anticancer agents.
Purpose of the Study:
- To review emerging preclinical models for cancer drug development.
- To provide an overview of recently developed oncology drugs.
Main Methods:
- Utilizing advanced preclinical models such as those replicating immune-tumor interactions.
- Employing 3D cell cultures and microfluidic platforms to study cancer biology.
- Analyzing the interplay between cancer and stromal cells.
Main Results:
- Preclinical models are crucial for developing immunotherapies and combination therapies.
- New drugs, including antibody-drug conjugates (ADCs), immunotherapies, and molecular-targeted therapies, are advancing in clinical research.
- Improved preclinical models facilitate accurate selection of drug candidates.
Conclusions:
- Enhanced preclinical models will improve the selection of drug candidates for clinical trials.
- Innovative oncology drugs are progressing through development phases.
- A patient-centered clinical research model is needed for faster access to innovations and targeted trials.
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:26Drug Discovery: Overview
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:28Preclinical Development: Overview